Testosterone injectable market is gaining acceptance among patients and physicians due to increasing awareness regarding benefits and efficacy of testosterone replacement therapy products.
The primary male hormone responsible for improving male sexual traits, spermatogenesis, and fertility is testosterone. Erectile dysfunction is caused by a lack of testosterone production, which can be treated with testosterone injectable.
The demand for testosterone injectable market is largely based on the rise in geriatric population with high risk of testosterone deficiency, growing awareness about testosterone injectable, improved health care infrastructure, policies, and advancement in health care infrastructure. Moreover, access to various diagnostic and treatment services has improved in the recent past, especially in developed economies and this is one of the major factor that has boosted the demand for testosterone injectable market.
The market for testosterone injectable is most prominently driven by countries like U.S. According to a study published in the European Association of Urology Journal, testosterone treatment patterns in the United States have increased by 1.8 to 4-fold in the last two decades.
Moreover, there is an increasing number of people suffering from hypogonadism, growing geriatric population and growing availability of effective and convenient treatment options results in an increasing demand for testosterone injectable in the U.S. The U.S. is undertaking a variety of attempts to strengthen their research and development facilities to fulfil the demand for testosterone injectable.
Europe Demand Outlook for Testosterone Injectable Market
As per a study published in the National Center for Biotechnology Information (NCBI), approximately 30% of men worldwide are affected by hypogonadism. Europe accounts for the existence of numerous medical centers, robust healthcare infrastructure, and increasing government initiative.
Furthermore, rising rise in the incidence of testosterone deficiency, increase in geriatric population with high risk of testosterone deficiency, and increasing awareness about testosterone substitute therapy are the key driving factors in testosterone injectable market in Europe.
The key companies working in testosterone injectable and solutions for testosterone injectable are
- Clarus Therapeutics
- Bayer AG
- Endo Pharmaceuticals Inc.
- Eli Lilly Company
- Kyowa Kirin International plc
- Mylan N.V.
- Novartis AG
- and Pfizer Inc.
- J & K Scientific Ltd.
- Beijing Coupling Technology Co.Ltd.
- Longyan Tianhua Biological Technology Co.Ltd
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14052
Manufacturers in the market focus on carrying out certain strategic activities such as acquisitions and mergers, expansion, product launch, etc. For instance, on May 25, 2020, Partner Perspectives announced the latest innovation in Testosterone Replacement Therapy (TRT) is JATENZO®, an oral softgel formulation of testosterone undecanoate (TU) for adult males for conditions associated with a deficiency or absence of endogenous testosterone.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may take time to reflect in the analysis.
By Dosage Form:
- Autoimmune Conditions
- Genetic Disorders
- Sex Organ Surgeries
By Drug Active Ingredient:
- Testosterone Cypionate
- Testosterone Undecanoate
- Testosterone Enanthate
- Methyl testosterone
By Age Group:
By End User:
- Specialty Clinics
For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14052
- North America
- Latin America
- South Asia
- East Asia
- The Middle East and Africa